Markets:

Overview

News

Currencies

International

Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.14 -0.17 (-1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 Next >

Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M ↗

June 26, 2024

Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth...

Via Benzinga

India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. ↗

June 03, 2024

Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.

Via Investor's Business Daily

RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 ↗

May 07, 2024

RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

Via InvestorPlace

Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand ↗

February 22, 2024

Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by...

Via Benzinga

Topics Intellectual Property

Dr Reddy's Laboratories: Q3 Earnings Insights ↗

January 30, 2024

Via Benzinga

Is NYSE:RDY suited for quality investing? ↗

September 14, 2023

Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics.

Via Chartmill

Should you consider NYSE:RDY for quality investing? ↗

August 21, 2023

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article.

Via Chartmill

Chart Of The Day: What's Cooking At Dr. Reddy's Lab ↗

July 28, 2023

100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha

Via Talk Markets

Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. ↗

October 24, 2023

Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors.

Via Chartmill

Top 5 Health Care Stocks That May Fall Off A Cliff ↗

August 23, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Why Are Journey Medical Shares Trading Lower Today? ↗

July 11, 2023

Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release...

Via Benzinga

Why Are Journey Medical Shares Trading Higher Today ↗

June 13, 2023

Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the

Via Benzinga

The 3 Most Undervalued Value Stocks to Buy in June 2023 ↗

June 04, 2023

One positive aspect about broader market challenges is the rising opportunity in the best undervalued value stocks for June.

Via InvestorPlace

Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗

May 13, 2023

Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....

Via Talk Markets

Intercept Settles Ocaliva Litigation With Reddy's Lab ↗

August 17, 2022

Via Benzinga

India Based Pharma Companies In Race To Buy Athenex, Shares Surge ↗

August 05, 2022

Via Benzinga

Why Aditxt Shares Are Surging Today ↗

April 20, 2023

Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases.

Via Benzinga

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

March 23, 2023

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

Via News Direct

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development ↗

March 22, 2023

Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.

Via Benzinga

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

March 21, 2023

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

Via News Direct

Eton Pharma Shares Tick Higher After Offloading Hospital Products ↗

June 24, 2022

Via Benzinga

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 ↗

March 20, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.

Via Benzinga

Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal ↗

February 27, 2023

Via Benzinga

The 3 Most Undervalued Stocks in India for Your February Buy List ↗

January 31, 2023

These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years.

Via InvestorPlace

Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years ↗

January 25, 2023

Intercept entered a deal with Amneal, likely lining up a series of new settlements.

Via Investor's Business Daily

Journey Medical Touts Positive PK Data For Bacterial Infection Candidate ↗

December 20, 2022

Via Benzinga

Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug ↗

October 14, 2022

The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

August 05, 2022

Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!

Via InvestorPlace

Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients ↗

May 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

Headline News about Dr. Reddy's Laboratories Ltd Common Stock

Starting at $3.75/week.

Subscribe Today